|
Study | Patients | Lesions | Tumor volume or size (median) | Type of mets | Dose | Median FU | LC | OS | Toxicity |
|
Blomgren et al. (1995) [14] | 14 | 17 | 3–260 mL | CRC (11) Anal canal (1) Kidney (1) Ovarian (1) | 7.7–45 Gy (1–4 fx) | 9.6 mo | NR-50% response rate | NR | 2 cases of hemorrhagic gastritis |
|
Wulf et al. (2006) [15] | 44 (39 liver mets) | 51 | 9–355 mL | CRC (23) Breast (11) Ovarian (4) Other (13) | 30–37.5 Gy (3 fx) 26 Gy (1 fx) | 2 yr | 1-yr LC, 92%, 2-yr LC, 66% | 1-yr OS, 72% 2-yr OS, 32% | No grade 2–4 toxicity |
|
Katz et al. (2007) [16] | 69 | 174 | 0.6–12.5 cm (2.7 cm) | CRC (20) Breast (16) Pancreas (9) Lung (5) Other (19) | 30–55 Gy (5–15 fx) | 14.5 mo | 10-mo LC, 76%, 20-mo LC, 57% | Median survival, 14.5 mo, 6-mo OS, 46%, 12-mo OS, 24% | No grade 3/4 toxicity |
|
van der Pool et al. (2010) [17] | 20 | 31 | 0.7–6.2 cm (2.3 cm) | All CRC | 30–37.5 Gy (3 fx) | 26 mo | 1-yr LC, 100%, 2-yr LC, 74% | Median survival, 34 mo, 1-yr OS, 100%, 2-yr OS, 83% | 2 grade 3 late liver enzyme changes, 1 grade 2 rib fracture |
|
Chang et al. (2011) [18] | 65 | 102 | 0.6–3088 mL (30.1 mL) | All CRC | 22–60 Gy (1–6 fx) | 14.4 mo | 1-yr LC, 62%, 2-yr LC, 45% | 1-yr OS, 72%, 2-yr OS, 38% | 2 grade 3 gastritis, 2 grade 3 elevated liver enzymes. |
|
Vautravers-Dewas et al. (2011) [19] | 42 | 62 | 0.7–10 cm (3.4 cm) | | 40 Gy (4 fx) 45 Gy (3 fx) | 14.3 mo | 2-yr LC, 86% | 2-yr OS, 48% | |
|
Lanciano et al. (2012) [20] | 30 (23 liver mets) | 41 | 2.29–316 mL (60.9 mL) | CRC (15) Breast (3) Esophagus (1) GIST (1) Pancreas (1) NSCLC (2) | 36–60 Gy (3 fx) 50 Gy (5 fx) | 22 mo | 1-yr LC, 92%, 2-yr LC, 56% | 1-yr OS, 73%, 2-yr OS, 31% | No grade 3/4 toxicity |
|
Habermehl et al. (2013) [21] | 90 | 138 | 11–333 mL (62 mL) | CRC (70) Breast (27) Pancreas (11) Ovarian (7) Lung (6) Others (16), by site | 10–30 Gy (1 fx) | 21.7 mo | 87%, 69%, and 59% after 6, 12, and 18 mo | Median OS 24.3 mo; local PFS was 87%, 70%, and 59% after 6, 12, and 18 mo, respectively | No RILD |
|